Virpax Pharmaceuticals, Inc.
VRPX evidence brief
What we can confirm
- BioSniper Score:
- 5.3 / 10
- Market Cap:
- $14K
- Lead Asset:
- anqlar (Preclinical)
What it means
What to watch
Prepared research question
What matters most for VRPX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$14K
Cash Runway
—
Lead Asset
anqlar (Preclinical)
Next Catalyst
—
Tracking 5 pipeline candidates for Virpax Pharmaceuticals, Inc..
Run Virpax Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Virpax Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Preclinical
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of May 22, 2026- % of float
- 1.8%
- Days to cover
- 0.0
- Shares short
- 23,082
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VRPX short interestGovernance
Frequently asked questions
What is Virpax Pharmaceuticals, Inc.'s lead drug candidate?
Virpax Pharmaceuticals, Inc.'s most advanced tracked candidate is anqlar (Preclinical) for prophylactic viral barrier to inhibit viral infection by influenza or SARS-CoV-2.
Who is the CEO of Virpax Pharmaceuticals, Inc.?
Mr. Jatinder Dhaliwal is the chief executive officer of Virpax Pharmaceuticals, Inc. (VRPX).
Where is Virpax Pharmaceuticals, Inc. headquartered?
Virpax Pharmaceuticals, Inc. (VRPX) is headquartered in Berwyn, PA, United States.
What therapeutic areas does Virpax Pharmaceuticals, Inc. focus on?
Virpax Pharmaceuticals, Inc. develops therapies across Oncology, Neurology, Infectious Disease, Pain, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.